BiotechTube
CimCure

CimCure

Phase 1/2
Maastricht, NetherlandsFounded 201610-20 employeescimcure.com

CimCure, a 2016 spin-off from Amsterdam UMC, is pioneering an anti-angiogenic immunotherapy approach to cancer. The company's core iBoost technology fuses a foreign protein to a tumor-specific endothelial protein, triggering a potent antibody response that destroys the tumor vasculature. Having secured seed investment and an innovation credit, CimCure is advancing its lead vaccine CVx1 into clinical trials, aiming for a broadly applicable treatment for solid tumors.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Funding information not available

AI Company Overview

CimCure, a 2016 spin-off from Amsterdam UMC, is pioneering an anti-angiogenic immunotherapy approach to cancer. The company's core iBoost technology fuses a foreign protein to a tumor-specific endothelial protein, triggering a potent antibody response that destroys the tumor vasculature. Having secured seed investment and an innovation credit, CimCure is advancing its lead vaccine CVx1 into clinical trials, aiming for a broadly applicable treatment for solid tumors.

Oncology

Technology Platform

iBoost conjugate vaccine platform that fuses a foreign protein to tumor-specific endothelial markers, inducing an antibody response that destroys the tumor's blood supply (anti-angiogenesis).

Opportunities

The iBoost platform's potential for broad application across solid tumors represents a massive market opportunity.
Positive clinical data could enable expansion into multiple high-incidence cancers and attract lucrative partnership deals with big pharma.
The demonstrated efficacy in canine oncology also opens a parallel, near-term veterinary market.

Risk Factors

Primary risks include clinical failure of the novel CVx1 mechanism in human trials, the challenge of demonstrating superiority over established therapies, future financing needs leading to shareholder dilution, and the regulatory complexity of developing a potentially broad-label cancer vaccine.

Competitive Landscape

CimCure faces limited direct competition in the niche of anti-angiogenic cancer vaccines. It differentiates from mainstream T-cell-focused cancer vaccine companies (e.g., BioNTech) and monoclonal antibody anti-angiogenics (e.g., bevacizumab) through its conjugate vaccine platform designed to induce a durable, resistance-free antibody response against the tumor vasculature.